SynthesisAnnals of hematology2025

Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model.

Lazaros Karatisidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.